Table 1.
Comparison between baseline characteristics of patients undergoing MIMH with neoadjuvant versus no-neoadjuvant chemotherapy for colorectal liver metastases
| Entire unmatched cohort | 1:1 coarsened exact matching | 1:2 propensity-score matching | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All N = 1034 |
NAT (N = 641) | Non-NAT (N = 393) | P-value | NAT (N = 93) | Non-NAT (N = 93) | P-value | Neoadjuvant (N = 334) | Non-NAT (N = 167) | P-value | |
| Mean age (SD), years | 65 (56–73) | 64 (55–72) | 65 (58–74) | 0.019 | 66 (58–73) | 67 (58–77) | 0.584 | 64 (55–71) | 66 (52–74) | 0.349 |
| Male sex, n (%) | 595 (57.5%) | 351 (54.8%) | 244 (62.1%) | 0.021 | 51 (54.8%) | 51 (54.8%) | 1.000 | 184 (55.1%) | 85 (50.9%) | 0.376 |
| Robotic, n (%) Laparoscopic, n (%) |
156 (15.1%) 878 (84.9%) |
74 (11.5%) 567 (88.5%) |
82 (20.9%) 311 (79.1%) |
<0.001 | 3 (3.2%) 90 (96.8%) |
3 (3.2%) 90 (96.8%) |
1.000 | 38 (11.4%) 296 (88.6%) |
18 (10.8%) 149 (89.2%) |
0.840 |
| Year of surgery, n (%) 2005–2010 2011–2015 2016–2021 |
83 (8.0%) 313 (30.3%) 638 (61.7%) |
53 (8.3%) 211 (32.9%) 377 (58.8%) |
30 (7.6%) 102 (26.0%) 261 (66.4%) |
0.043 |
3 (3.2%) 27 (29.0%) 63 (67.7%) |
3 (3.2%) 27 (29.0%) 63 (67.7%) |
1.000 |
30 (9.0%) 115 (34.4%) 189 (56.6%) |
16 (9.6%) 57 (34.1%) 94 (56.3%) |
0.976 |
| Previous abdominal surgery, n (%) | 420 (65.5%) | 277 (70.5%) | 277 (70.5%) | 0.099 | 68 (73.1%) | 68 (73.1%) | 1.000 | 237 (71.0%) | 106 (63.5) | 0.164 |
| ASA score, n (%) 1–2 3–4 |
725 (70.1%) 309 (29.9%) |
441 (68.8%) 200 (31.2%) |
284 (72.3%) 109 (27.7%) |
0.237 |
8 (83.9%) 15 (16.1%) |
8 (83.9%) 15 (16.1%) |
1.000 |
233 (69.8%) 101 (30.2%) |
118 (70.7%) 49 (29.3%) |
0.836 |
| Median tumor size, mm (IQR) | 36 (24–55) | 34 (20–53) | 40 (28–58) | <0.001 | 40 (28–60) | 40 (30–58) | 0.869 | 33 (20–54) | 32 (20–54) | 0.939 |
| Multiple tumors, n (%) | 557 (53.9%) | 394 (61.5%) | 163 (41.5%) | <0.001 | 41 (44.1%) | 41 (44.1%) | 1.000 | 209 (62.6%) | 100 (59.9%) | 0.558 |
| Concomitant minor surgery, n (%) | 83 (8.0%) | 62 (9.7%) | 21 (5.3%) | 0.013 | 3 (3.2%) | 3 (3.2%) | 1.000 | 29 (8.7%) | 11 (6.6%) | 0.411 |
| Traditional major (>3 segments), n (%) | 774 (74.9%) | 510 (79.6%) | 264 (67.2%) | <0.001 | 58 (62.4%) | 58 (62.4%) | 1.000 | 271 (81.1%) | 129 (77.2%) | 0.306 |
| Technical major (RAS/RPS), n (%) | 260 (25.1%) | 131 (20.4%) | 129 (32.8%) | <0.001 | 35 (37.6%) | 35 (37.6%) | 1.000 | 63 (18.9%) | 38 (22.8%) | 0.306 |
| Difficult segments (I, IVa, VII, VIII), n (%) | 825 (79.8%) | 537 (83.8%) | 288 (73.3%) | <0.001 | 77 (82.8%) | 77 (82.8%) | 1.000 | 278 (83.2%) | 142 (85.0%) | 0.607 |
| Multiple liver resections (up to 2), n (%) | 148 (14.3%) | 118 (18.4%) | 30 (7.6%) | <0.001 | 8 (8.6%) | 8 (8.6%) | 1.000 | 62 (18.6%) | 31 (18.6%) | 1.000 |
| Median Iwate difficulty score, (range) | 10 (9–11) | 10 (9–11) | 10 (9–11) | 0.142 | 10 (9–11) | 10 (9–11) | 0.587 | 10 (9–11) | 10 (9–11) | 0.924 |
| Iwate difficulty, n (%) Intermediate High Expert |
22 (2.1%) 387 (37.5%) 623 (60.4%) |
11 (1.7%) 230 (35.9%) 399 (62.3%) |
11 (2.8%) 157 (40.1%) 224 (57.1%) |
0.171 |
1 (1.1%) 23 (24.7%) 69 (74.2%) |
1 (1.1%) 23 (24.7%) 69 (74.2%) |
1.000 |
9 (2.7%) 123 (36.8%) 202 (60.5%) |
1 (0.6%) 68 (40.7%) 98 (58.7%) |
0.229 |
| IMM difficulty, n (%) II III |
234 (22.6%) 800 (77.4%) |
124 (19.3%) 517 (80.7%) |
110 (28.0%) 283 (72.0%) |
0.003 |
16 (17.2%) 93 (82.8%) |
16 (17.2%) 93 (82.8%) |
1.000 |
67 (20.1%) 267 (79.9%) |
38 (22.8%) 129 (77.2%) |
0.485 |
*
NAT-Neoadjuvant chemotherapy; SD - Standard Deviation; ASA - American Society of Anesthesiologists; IQR - interquartile range; RAS - right anterior sectionectomy; RPS - right posterior sectionectomy; IMM - Institut Mutualiste Montsouris.